The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention

An intent-to-treat analysis of the DPP/DPPOS

William H. Herman, Sharon L. Edelstein, Robert E. Ratner, Maria G. Montez, Ronald T. Ackermann, Trevor J. Orchard, Mary A. Foulkes, Ping Zhang, Christopher D. Saudek, Morton B. Brown

Research output: Contribution to journalArticle

239 Citations (Scopus)

Abstract

OBJECTIVE - The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions.RESEARCH DESIGN ANDMETHODS - Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives.RESULTS - Over 10 years, the cumulative, undiscounted per capita directmedical costs of the interventions, as implemented during the DPP,were greater for lifestyle ($4,601) than metformin ($2,300) or placebo ($769). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($24,563 lifestyle vs. $25,616 metformin vs. $27,468 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($29,164 lifestyle vs. $27,915 metformin vs. $28,236 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.81) than metformin (6.69) or placebo (6.67). When costs and outcomes were discounted at 3%, lifestyle cost $10,037 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo.CONCLUSIONS - Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metformin interventions for diabetes prevention in high-risk adults provides good value for the money spent.

Original languageEnglish (US)
Pages (from-to)723-730
Number of pages8
JournalDiabetes Care
Volume35
Issue number4
DOIs
StatePublished - Apr 2012

Fingerprint

Metformin
Cost-Benefit Analysis
Life Style
Outcome Assessment (Health Care)
Costs and Cost Analysis
Placebos
Quality-Adjusted Life Years
Random Allocation
Health Care Costs
Type 2 Diabetes Mellitus
Economics
Quality of Life

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Advanced and Specialized Nursing

Cite this

Herman, W. H., Edelstein, S. L., Ratner, R. E., Montez, M. G., Ackermann, R. T., Orchard, T. J., ... Brown, M. B. (2012). The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS. Diabetes Care, 35(4), 723-730. https://doi.org/10.2337/dc11-1468

The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention : An intent-to-treat analysis of the DPP/DPPOS. / Herman, William H.; Edelstein, Sharon L.; Ratner, Robert E.; Montez, Maria G.; Ackermann, Ronald T.; Orchard, Trevor J.; Foulkes, Mary A.; Zhang, Ping; Saudek, Christopher D.; Brown, Morton B.

In: Diabetes Care, Vol. 35, No. 4, 04.2012, p. 723-730.

Research output: Contribution to journalArticle

Herman, WH, Edelstein, SL, Ratner, RE, Montez, MG, Ackermann, RT, Orchard, TJ, Foulkes, MA, Zhang, P, Saudek, CD & Brown, MB 2012, 'The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS', Diabetes Care, vol. 35, no. 4, pp. 723-730. https://doi.org/10.2337/dc11-1468
Herman, William H. ; Edelstein, Sharon L. ; Ratner, Robert E. ; Montez, Maria G. ; Ackermann, Ronald T. ; Orchard, Trevor J. ; Foulkes, Mary A. ; Zhang, Ping ; Saudek, Christopher D. ; Brown, Morton B. / The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention : An intent-to-treat analysis of the DPP/DPPOS. In: Diabetes Care. 2012 ; Vol. 35, No. 4. pp. 723-730.
@article{3e8a6fce9e794d9d9a28f891d69caa4c,
title = "The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention: An intent-to-treat analysis of the DPP/DPPOS",
abstract = "OBJECTIVE - The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions.RESEARCH DESIGN ANDMETHODS - Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives.RESULTS - Over 10 years, the cumulative, undiscounted per capita directmedical costs of the interventions, as implemented during the DPP,were greater for lifestyle ($4,601) than metformin ($2,300) or placebo ($769). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($24,563 lifestyle vs. $25,616 metformin vs. $27,468 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($29,164 lifestyle vs. $27,915 metformin vs. $28,236 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.81) than metformin (6.69) or placebo (6.67). When costs and outcomes were discounted at 3{\%}, lifestyle cost $10,037 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo.CONCLUSIONS - Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metformin interventions for diabetes prevention in high-risk adults provides good value for the money spent.",
author = "Herman, {William H.} and Edelstein, {Sharon L.} and Ratner, {Robert E.} and Montez, {Maria G.} and Ackermann, {Ronald T.} and Orchard, {Trevor J.} and Foulkes, {Mary A.} and Ping Zhang and Saudek, {Christopher D.} and Brown, {Morton B.}",
year = "2012",
month = "4",
doi = "10.2337/dc11-1468",
language = "English (US)",
volume = "35",
pages = "723--730",
journal = "Diabetes Care",
issn = "1935-5548",
publisher = "American Diabetes Association Inc.",
number = "4",

}

TY - JOUR

T1 - The 10-year cost-effectiveness of lifestyle intervention or metformin for diabetes prevention

T2 - An intent-to-treat analysis of the DPP/DPPOS

AU - Herman, William H.

AU - Edelstein, Sharon L.

AU - Ratner, Robert E.

AU - Montez, Maria G.

AU - Ackermann, Ronald T.

AU - Orchard, Trevor J.

AU - Foulkes, Mary A.

AU - Zhang, Ping

AU - Saudek, Christopher D.

AU - Brown, Morton B.

PY - 2012/4

Y1 - 2012/4

N2 - OBJECTIVE - The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions.RESEARCH DESIGN ANDMETHODS - Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives.RESULTS - Over 10 years, the cumulative, undiscounted per capita directmedical costs of the interventions, as implemented during the DPP,were greater for lifestyle ($4,601) than metformin ($2,300) or placebo ($769). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($24,563 lifestyle vs. $25,616 metformin vs. $27,468 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($29,164 lifestyle vs. $27,915 metformin vs. $28,236 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.81) than metformin (6.69) or placebo (6.67). When costs and outcomes were discounted at 3%, lifestyle cost $10,037 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo.CONCLUSIONS - Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metformin interventions for diabetes prevention in high-risk adults provides good value for the money spent.

AB - OBJECTIVE - The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions.RESEARCH DESIGN ANDMETHODS - Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives.RESULTS - Over 10 years, the cumulative, undiscounted per capita directmedical costs of the interventions, as implemented during the DPP,were greater for lifestyle ($4,601) than metformin ($2,300) or placebo ($769). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($24,563 lifestyle vs. $25,616 metformin vs. $27,468 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($29,164 lifestyle vs. $27,915 metformin vs. $28,236 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.81) than metformin (6.69) or placebo (6.67). When costs and outcomes were discounted at 3%, lifestyle cost $10,037 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo.CONCLUSIONS - Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metformin interventions for diabetes prevention in high-risk adults provides good value for the money spent.

UR - http://www.scopus.com/inward/record.url?scp=84861776112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861776112&partnerID=8YFLogxK

U2 - 10.2337/dc11-1468

DO - 10.2337/dc11-1468

M3 - Article

VL - 35

SP - 723

EP - 730

JO - Diabetes Care

JF - Diabetes Care

SN - 1935-5548

IS - 4

ER -